Updated results of the FIRIS study: A phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC).

Phase Ii ◽

Second Line ◽

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

International Journal of Clinical Oncology ◽

10.1007/s10147-015-0943-z ◽

2016 ◽

Vol 21 (4) ◽

pp. 705-712 ◽

Cited By ~ 3

Author(s):

Yuji Miyamoto ◽

Akihito Tsuji ◽

Hiroaki Tanioka ◽

Soichiro Maekawa ◽

Hirofumi Kawanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

International Journal of Clinical Oncology ◽

10.1007/s10147-017-1212-0 ◽

2017 ◽

Vol 23 (2) ◽

pp. 402-402

Author(s):

Yuji Miyamoto ◽

Akihito Tsuji ◽

Hiroaki Tanioka ◽

Soichiro Maekawa ◽

Hirofumi Kawanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

S-1 and CPT-11 plus ramucirumab (IRIS+Rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: A multicenter phase II study in Japan (N-DOCC-F-C-1701)

Annals of Oncology ◽

10.1093/annonc/mdx659.049 ◽

2017 ◽

Vol 28 ◽

pp. x56

Author(s):

K. Kobayashi ◽

M. Morita ◽

S. Ito ◽

Y. Inoue ◽

I. Yamaguchi ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

Multicenter phase II study of irinotecan as second line chemotherapy in metastatic colorectal cancer after prior exposure to infusional 5-FU based chemotherapy

European Journal of Cancer ◽

10.1016/s0959-8049(01)81572-0 ◽

2001 ◽

Vol 37 ◽

pp. S293

Author(s):

P. Schöffski ◽

U. Vanhoefer ◽

H. Kirchner ◽

G. Trenn ◽

C. Bokemeyer ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Prior Exposure ◽

Second Line ◽

Multicenter Phase ◽

S-1 and CPT-11 Plus Ramucirumab (IRIS+Rmab) as Second-Line Chemotherapy for Patients with Oxaliplatin-Refractory Metastatic Colorectal Cancer (mCRC): A Multicenter Phase II Study in Japan (N-DOCC-F-C-1701)

The Kurume Medical Journal ◽

10.2739/kurumemedj.ms661007 ◽

2019 ◽

Vol 66 (1) ◽

pp. 43-47

Author(s):

KAZUMA KOBAYASHI ◽

MICHI MORITA ◽

SAEKO FUKUI ◽

SHINICHIRO ITO ◽

YUSUKE INOUE ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

A Phase I/II Study of BI-Weekly Xeliri Plus Bevacizumab for Patient with Metastatic Colorectal Cancer as Second-Line Chemotherapy (Bixer Study): Reports of Interim Analysis of Phase II Part

Annals of Oncology ◽

10.1016/s0923-7534(20)32376-0 ◽

2012 ◽

Vol 23 ◽

pp. xi130-xi131

Author(s):

M. Suenaga ◽

S. Matsusaka ◽

E. Shinozaki ◽

M. Ozaka ◽

M. Ogura ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase I ◽

Phase Ii ◽

Interim Analysis ◽

Second Line ◽

Validation Study of a Prognostic Classification System in Patients with Metastatic Colorectal Cancer who Received Irinotecan-Based Second-Line Chemotherapy

Annals of Oncology ◽

10.1016/s0923-7534(20)32206-7 ◽

2012 ◽

Vol 23 ◽

pp. xi87

Author(s):

Y. Naito ◽

K. Shitara ◽

K. Yamazaki ◽

S. Yuki ◽

H. Yasui ◽

...

Keyword(s):

Colorectal Cancer ◽

Validation Study ◽

Classification System ◽

Second Line ◽

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

Investigational New Drugs ◽

10.1007/s10637-010-9400-z ◽

2010 ◽

Vol 29 (5) ◽

pp. 1038-1044 ◽

Cited By ~ 9

Author(s):

José María Viéitez ◽

Manuel Valladares ◽

Ignacio Peláez ◽

Luis de Sande González ◽

Jesús García-Foncillas ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Randomized Phase Ii ◽

Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]

European Journal of Cancer ◽

10.1016/j.ejca.2011.12.001 ◽

2012 ◽

Vol 48 (3) ◽

pp. 407

Author(s):

Stephen J. Clarke ◽

Sonia Yip ◽

Chris Brown ◽

Guy A. van Hazel ◽

David T. Ransom ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Phase Ii Study ◽

Meta Analysis ◽

Single Agent ◽

Second Line ◽

A Phase I/II Study of Bi-Weekly Xeliri with Capecitabine 1,000 Mg/M2 Twice Daily and Irinotecan 180 Mg/M2 Plus Bevacizumab(Bv) for Patient with Metastatic Colorectal Cancer As Second-Line Chemotherapy (Bixer Study)

Annals of Oncology ◽

10.1093/annonc/mdu333.30 ◽

2014 ◽

Vol 25 ◽

pp. iv179

Author(s):

M. Suenaga ◽

N. Mizunuma ◽

S. Matsusaka ◽

E. Shinozaki ◽

M. Ozaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase I ◽

Second Line ◽